# US 2016/0251379 A1 · Molecular switches based on cis/trans isomerization of bf2-coordinated azo compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0251379 A1
- Document ID: US20160251379A1
- Status: Published application
- Kind: A1
- Application number: 15/056,580
- Filed: 2016-02-29
- Published: 2016-09-01
- Earliest claimed: 2013-08-27
- Assignees: Trustees of Dartmouth College
- Applicants: The Trustees of Dartmouth College
- Inventors: Ivan Abrahamian; Russel P. Hughes; Yin Yang
- Web page: https://patentgrep.com/patent/US20160251379A1

## CPC

- C07F 5/022: {without C-boron linkages}
- A61N 5/062: {Photodynamic therapy, i.e. excitation of an agent}
- C07F 5/02: Boron compounds
- A61N 2005/066: {far infrared}
- A61N 2005/0662: {Visible light}
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

Provided herein are photochromic organic compounds of Formula I or Formula II, which are useful as molecular switches capable of being triggered via a cis/trans isomerization process. Methods of using the molecular switch compounds to form photopharmaceutical compounds that may be used to provide selective spatiotemporal activation of pharmaceutical agents are also disclosed.

## Claims

### Claim 1

A compound of the Formula II:
or a salt thereof, wherein
N═N—R2 can be oriented cis or trans to the tricycle;
R1 is H, CN, CO2H, CO2(C1-6-alkyl), C1-6-alkyl, C6-19-aryl, OH, O(C1-6-alkyl), OC(O)(C1-6-alkyl), NH2, NH(C1-6-alkyl), N(C1-6-alkyl)2, or NHC(O)(C1-6-alkyl);
R2 is C6-19-aryl or C3-14-heteroaryl; and
R3, R4, R5, R6, R7 and R8 are each, independently, H, C1-6-alkyl, C6-19-aryl, OH, O(C1-6-alkyl), OC(O)(C1-6-alkyl), NH2, NH(C1-6-alkyl), N(C1-6-alkyl)2, NHC(O)(C1-6-alkyl) or a group corresponding to a small molecule pharmaceutical; or
R3 and R4, R4 and R5, R5 and R6 or R7 and R8 can, when taken together, form a fused aryl, fused heteroaryl, fused C3-6-cycloalkyl, or fused heterocycle, wherein the fused aryl, fused heteroaryl, fused cycloalkyl, or fused heterocycle can be optionally substituted one or more times with C1-6-alkyl, C6-19-aryl, OH, O(C1-6-alkyl), OC(O)(C1-6-alkyl), NH2, NH(C1-6-alkyl), N(C1-6-alkyl)2, or NHC(O)(C1-6-alkyl).

### Claim 2 (depends on 1)

The compound of claim 1, wherein R2 is unsubstituted C6-19-aryl or unsubstituted C3-14-heteroaryl.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R3, R4, R5, R6, R7 and R8 are each, independently, H.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R1 is CN.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R2 is phenyl, wherein the phenyl is substituted with N(C1-6-alkyl)2, O(C1-6-alkyl), piperazinyl, (N-methyl)piperazinyl, piperidinyl, morpholinyl or a group corresponding to a cholesterol molecule.

### Claim 6 (depends on 1)

The compound of claim 1, wherein R2 is phenyl, wherein the phenyl is substituted at the para position with N(CH3)2, OCH3, piperazinyl, (N-methyl)piperazinyl, piperidinyl, morpholinyl or a group corresponding to a cholesterol molecule.

### Claim 7 (depends on 1)

The compound of claim 1, wherein N═N—R2 is oriented cis to the tricycle.

### Claim 8 (depends on 1)

The compound of claim 1, wherein N═N—R2 is oriented trans to the tricycle.

### Claim 9 (depends on 1)

The compound of claim 1, wherein R2 is unsubstituted phenyl.

### Claim 10

A photochromic molecular switch comprising at least one compound of the Formula II:
or a salt thereof, wherein
N═N—R2 can be oriented cis or trans to the tricycle;
R1 is H, CN, CO2H, CO2(C1-6-alkyl), C1-6-alkyl, C6-19-aryl, OH, O(C1-6-alkyl), OC(O)(C1-6-alkyl), NH2, NH(C1-6-alkyl), N(C1-6-alkyl)2, or NHC(O)(C1-6-alkyl);
R2 is C6-19-aryl or C3-14-heteroaryl; and
R3, R4, R5, R6, R7 and R8 are each, independently, H, C1-6-alkyl, C6-19-aryl, OH, O(C1-6-alkyl), OC(O)(C1-6-alkyl), NH2, NH(C1-6-alkyl), N(C1-6-alkyl)2, or NHC(O)(C1-6-alkyl); or
R3 and R4, R4 and R5, R5 and R6 or R7 and R8 can, when taken together, form a fused aryl, fused heteroaryl, fused C3-6-cycloalkyl, or fused heterocycle, wherein the fused aryl, fused heteroaryl, fused cycloalkyl, or fused heterocycle can be optionally substituted one or more times with C1-6-alkyl, C6-19-aryl, OH, O(C1-6-alkyl), OC(O)(C1-6-alkyl), NH2, NH(C1-6-alkyl), N(C1-6-alkyl)2, or NHC(O)(C1-6-alkyl).

### Claim 11 (depends on 10)

The photochromic molecular switch of claim 10, wherein R2 is unsubstituted C6-19-aryl or unsubstituted C3-14-heteroaryl.

### Claim 12 (depends on 10)

The photochromic molecular switch of claim 10, wherein R3, R4, R5, R6, R7 and R8 are each, independently, H.

### Claim 13 (depends on 10)

The photochromic molecular switch of claim 10, wherein R1 is CN.

### Claim 14 (depends on 10)

The photochromic molecular switch of claim 10, wherein R2 is phenyl, wherein the phenyl is substituted with N(C1-6-alkyl)2, O(C1-6-alkyl), piperazinyl, (N-methyl)piperazinyl, piperidinyl, morpholinyl or a group corresponding to a cholesterol molecule.

### Claim 15 (depends on 10)

The photochromic molecular switch of claim 10, wherein R2 is phenyl, wherein the phenyl can be optionally substituted at the para position with N(CH3)2, OCH3, piperazinyl, (N-methyl)piperazinyl, piperidinyl, morpholinyl or a group corresponding to a cholesterol molecule.

### Claim 16 (depends on 10)

The photochromic molecular switch of claim 10, wherein N═N—R2 is oriented cis to the tricycle.

### Claim 17 (depends on 10)

The photochromic molecular switch of claim 10, wherein N═N—R2 is oriented trans to the tricycle.

### Claim 18 (depends on 10)

The photochromic molecular switch of claim 10, wherein R2 is unsubstituted phenyl.

### Claim 19

A method of switching a molecular switch, wherein the molecular switch comprises a compound of Formula I or salt thereof wherein the method comprises applying electromagnetic radiation to the molecular switch at a first wavelength effective to cause the trans→cis isomerization of the compound of Formula I or salt thereof or applying electromagnetic radiation to the molecular switch at a second wavelength effective to cause the cis→trans isomerization of the compound of Formula I or salt thereof or a combination thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein the electromagnetic radiation is generated by an infrared light source and/or a visible light source.

### Claim 21 (depends on 19)

The method of claim 19, wherein the electromagnetic radiation is generated by a visible light source.

### Claim 22 (depends on 20)

The method of claim 20, wherein the first wavelength (λ) is between 400 nanometers and 1000 nanometers.

### Claim 23 (depends on 20)

The method of claim 20, wherein the second wavelength (λ) is between 400 nanometers and 1000 nanometers.

### Claim 24 (depends on 20)

The method of claim 20, wherein the first wavelength (λ) is between 450 nanometers and 850 nanometers.

### Claim 25 (depends on 20)

The method of claim 20, wherein the second wavelength (λ) is between 450 nanometers and 850 nanometers.

### Claim 26 (depends on 10)

The molecular switch of claim 10, wherein the salt of Formula I is reacted with a pharmaceutically acceptable salt to form a photopharmaceutical compound.

### Claim 27 (depends on 27)

A method of treating a patient in need of therapy, comprising:
administering a therapeutically effective amount of the photopharmaceutical compound of claim 27 to a patient in need thereof; and
applying electromagnetic radiation to a tissue comprising the photopharmaceutical compound at a first wavelength effective to cause the trans→cis isomerization or applying electromagnetic radiation to the photopharmaceutical compound at a second wavelength effective to cause the cis→trans isomerization or a combination thereof, wherein one isomer has a higher binding affinity for a target of the tissue than the other isomer.

### Claim 28 (depends on 27)

The method of claim 27, wherein the electromagnetic radiation is generated by an infrared light source and/or a visible light source.

### Claim 29 (depends on 1)

The compound of claim 1, wherein the C6-19-aryl or C3-14-heteroaryl is independently substituted one or more times at the para and/or ortho position with C1-6-alkyl, C6-19-aryl, C3-14-heteroalkyl, OH, O(C1-6-alkyl), OC(O)(C1-6-alkyl), NH2, NH(C1-6-alkyl), N(C1-6-alkyl)2, or NHC(O)(C1-6-alkyl).

### Claim 30 (depends on 10)

The photochromic molecular switch of claim 10, wherein the C6-19-aryl or C3-14-heteroaryl is independently substituted one or more times at the para and/or ortho position with C1-6-alkyl, C6-19-aryl, C3-14-heteroalkyl, OH, O(C1-6-alkyl), OC(O)(C1-6-alkyl), NH2, NH(C1-6-alkyl), N(C1-6-alkyl)2, NHC(O)(C1-6-alkyl) or a group corresponding to a small molecule pharmaceutical.
